MedscapeNew Scoring System Evaluates Prognosis in Burkitt LymphomaMedscapeAdding rituximab to chemotherapy has improved both response and survival rates, but that has been difficult to conclusively demonstrate in small, single-arm, single-institution s…
IMMUNOMEDICS, INC. : EPRATUZUMAB AND RITUXIMAB PRODUCE HIGH …4-traders (press release)based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the combination of epratuzumab and rituximab, as a …
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …Wall Street JournalMORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of …
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …GlobeNewswire (press release)MORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the devel…
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …MarketWatchImmunomedics, Inc. (NASDAQ:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment …
Research and Markets: Cancer Monoclonal Antibodies Market Forecast to 2017Fort Mills TimesCancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. …
RESEARCH AND MARKETS: Cancer Monoclonal Antibodies Market Forecast to …4-traders (press release)Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million b…
The UK Rituximab Trial for MEProHealthNow, however, despite the power and control of the psychiatric lobby, thanks to Invest in ME and the invaluable support of Jonathan Edwards, Emeritus Professor of Connective Tissue Medicine at University College, L…
Rituximab shows long-term efficacy in antibody-associated vasculitismedwireNewsmedwireNews: A single course of rituximab is a viable alternative to conventional cyclophosphamide/azathioprine immunosuppression in patients with severe antineutrophil cyto…
Cancer Monoclonal Antibodies Market Forecast to 2017The Herald | HeraldOnline.comGlobal Cancer mAbs Market Outlook to 2017 7.1 Market Size 7.2 Cancer mAbs: Approval History and Market Share 7.3 Cancer mAbs: Current and Future Market Size 7.3.1 Avastin …